Both in Pharmaceuticals
PUMA BIOTECHNOLOGY vs Climb Bio
Over the past year PBYI returned +102.8% and CLYM returned +387.5%; their daily moves had a correlation of 0.21.
PBYI +102.8% CLYM +387.5%Growth of $1, one year, split-adjusted
| Metric | PBYI | CLYM |
|---|---|---|
| Price | $10.22 | $9.75 |
| Market cap | $527.6M | $560.0M |
| Today | +0.39% | +0.10% |
| 1 month | +5.7% | −11.8% |
| 6 months | +39.0% | −14.8% |
| Year to date | +71.8% | +143.8% |
| 1 year | +100.4% | +375.6% |
| Revenue growth (YoY) | +7.8% | — |
| Gross margin | 77.9% | — |
| Net margin | 14.5% | — |
| P/E (TTM) | 19.7× | — |
| Price / sales | 2.3× | — |
| Net cash | $93.9M | $183.1M |
| Dividend yield | — | — |
| Volatility (60d) | 39.5% | 80.7% |
| Short % of float | 11.6% | 25.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).